Latest Insider Transactions at Kiniksa Pharmaceuticals, Ltd. (KNSA)
This section provides a real-time view of insider transactions for Kiniksa Pharmaceuticals, Ltd. (KNSA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kiniksa Pharmaceuticals, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kiniksa Pharmaceuticals, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 02
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-0.5%
|
$6,347
$11.44 P/Share
|
|
Sep 02
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+1.68%
|
-
|
|
Sep 02
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
228
-3.03%
|
$2,508
$11.44 P/Share
|
|
Sep 02
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
775
+9.34%
|
-
|
|
Jul 15
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
360
+4.45%
|
$3,240
$9.56 P/Share
|
|
Jul 15
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,048
+0.92%
|
$9,432
$9.56 P/Share
|
|
Jul 15
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
703
+9.44%
|
$6,327
$9.56 P/Share
|
|
Jun 29
2022
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
20,000
+4.39%
|
-
|
|
Apr 26
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-4.25%
|
$2,538
$9.99 P/Share
|
|
Apr 26
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
991
+12.99%
|
-
|
|
Mar 21
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,461
-1.29%
|
$14,610
$10.98 P/Share
|
|
Mar 21
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,611
+3.9%
|
-
|
|
Mar 21
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-15.64%
|
$11,200
$10.98 P/Share
|
|
Mar 21
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,231
+31.09%
|
-
|
|
Mar 21
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,686
-4.58%
|
$16,860
$10.98 P/Share
|
|
Mar 21
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,676
+13.36%
|
-
|
|
Mar 21
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,047
-15.64%
|
$10,470
$10.98 P/Share
|
|
Mar 21
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,019
+31.08%
|
-
|
|
Mar 21
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,240
-14.4%
|
$12,400
$10.98 P/Share
|
|
Mar 21
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,270
+20.86%
|
-
|
|
Mar 21
2022
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,446
-23.47%
|
$54,460
$10.98 P/Share
|
|
Mar 21
2022
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,555
+44.44%
|
-
|
|
Mar 16
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
303
-7.62%
|
$3,030
$10.13 P/Share
|
|
Mar 16
2022
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
872
+17.98%
|
-
|
|
Mar 16
2022
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,922
-29.26%
|
$19,220
$10.13 P/Share
|
|
Mar 16
2022
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+50.0%
|
-
|
|
Mar 16
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
598
-1.88%
|
$5,980
$10.13 P/Share
|
|
Mar 16
2022
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+5.16%
|
-
|
|
Mar 16
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-0.62%
|
$6,810
$10.13 P/Share
|
|
Mar 16
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+1.76%
|
-
|
|
Mar 16
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
544
-7.9%
|
$5,440
$10.13 P/Share
|
|
Mar 16
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
995
+12.63%
|
-
|
|
Mar 16
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
269
-6.41%
|
$2,690
$10.13 P/Share
|
|
Mar 16
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
775
+15.58%
|
-
|
|
Jan 15
2022
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
970
+0.89%
|
$8,730
$9.63 P/Share
|
|
Jan 15
2022
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,546
+20.79%
|
$13,914
$9.63 P/Share
|
|
Jan 15
2022
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
653
+16.02%
|
$5,877
$9.63 P/Share
|
|
Jul 15
2021
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
868
+0.81%
|
$9,548
$11.49 P/Share
|
|
Jul 15
2021
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
963
+18.14%
|
$10,593
$11.49 P/Share
|
|
Jul 15
2021
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
588
+17.51%
|
$6,468
$11.49 P/Share
|
|
Feb 10
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
1,137
-1.35%
|
$26,151
$23.07 P/Share
|
|
Feb 10
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
1,600
-100.0%
|
$36,800
$23.06 P/Share
|
|
Feb 10
2021
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,600
+50.0%
|
$1,600
$1.59 P/Share
|
|
Feb 09
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
23,569
-21.81%
|
$542,087
$23.08 P/Share
|
|
Feb 09
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
20,401
-100.0%
|
$469,223
$23.04 P/Share
|
|
Feb 09
2021
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,401
+50.0%
|
$20,401
$1.59 P/Share
|
|
Feb 08
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
4,528
-4.02%
|
$104,144
$23.0 P/Share
|
|
Feb 08
2021
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
4,924
-100.0%
|
$113,252
$23.0 P/Share
|
|
Feb 08
2021
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,924
+50.0%
|
$4,924
$1.59 P/Share
|
|
Feb 03
2021
|
Thomas W. Beetham EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,477
-0.83%
|
$54,494
$22.09 P/Share
|